Drug search by name

Rituximab and hyaluronidase human, recombinant Subcutaneous and Hepatitis B

Result of checking the interaction of drug Rituximab and hyaluronidase human, recombinant Subcutaneous and disease Hepatitis B for safety when used together.

Check result:

Rituximab and hyaluronidase human, recombinant Subcutaneous <> Hepatitis B

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Rituximab, as other drugs classified as CD20-directed cytolytic antibodies can cause hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death. Cases have been reported in patients who are hepatitis B surface antigen (HBsAg) positive and in patients who are HBsAg negative but are hepatitis B core antibody (anti-HBc) positive. Reactivation also has occurred in patients who appear to have resolved hepatitis B infection (i.e., HBsAg negative, anti-HBc positive and hepatitis B surface antibody [anti-HBs] positive). Screen all patients for HBV infection by measuring HBsAg and anti-HBc before initiating treatment with rituximab. Monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following rituximab therapy. In patients who develop reactivation of HBV while on rituximab, immediately discontinue rituximab and any concomitant chemotherapy, and institute appropriate treatment.

Rituximab and hyaluronidase human, recombinant Subcutaneous

Generic Name: hyaluronidase / rituximab

Brand Name: Rituxan Hycela

Synonyms: Hyaluronidase and rituximab, Rituximab and Hyaluronidase

What is Rituximab and hyaluronidase human, recombinant Subcutaneous?